NICE recommendations

top of page

NICE Assessment Outcomes | 2026

NICE Assessment Outcomes | 2026

NICE Assessment Outcomes | 2026

Badari Andukuri

Aug 20

NICE Backs Donidalorsen for Hereditary Angioedema and Acalabrutinib for Blood Cancers

NICE Backs Donidalorsen for Hereditary Angioedema and Acalabrutinib for Blood Cancers

NICE Backs Donidalorsen for Hereditary Angioedema and Acalabrutinib for Blood Cancers

Badari Andukuri

Aug 19

NICE Backs Acalabrutinib for Mantle Cell Lymphoma and Untreated CLL

Badari Andukuri

Aug 6

UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy

Badari Andukuri

Jul 31

NICE Opens Access to New Immunotherapy in Cervical Cancer and First Disease‑Modifying Drug in Early Type 1 Diabetes

Badari Andukuri

Jun 28

NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive stomach cancer

NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive stomach cancer

NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive stomach cancer

ipharmaservices

May 14

NICE recommends Duvyzat for Duchenne muscular dystrophy

NICE recommends Duvyzat for Duchenne muscular dystrophy

NICE recommends Duvyzat for Duchenne muscular dystrophy

Badari Andukuri

May 9

NICE Recommends First Vitiligo Treatment for Use in the NHS

Badari Andukuri

Mar 3

NHS England lowers FIT threshold to catch more bowel cancers early

ipharmaservices

Jan 27

NICE greenlights Dupixent as add-on therapy for uncontrolled COPD with raised eosinophils in England, marking first targeted biologic for this indication | iPharmaCenter

ipharmaservices

Jan 27

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

Badari Andukuri

Dec 2, 2025

NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY

Badari Andukuri

Dec 1, 2025

NICE Approves Autolus’ Obe-cel CAR-T Therapy for Adults with Rare Blood Cancer | iPharmaCenter

ipharmaservices

Nov 25, 2025

NICE Recommends Vertex's £1.6 Million One-Time Gene Therapy Casgevy for Beta-Thalassaemia | iPharmaCenter

NICE Recommends Vertex's £1.6 Million One-Time Gene Therapy Casgevy for Beta-Thalassaemia | iPharmaCenter

NICE Recommends Vertex's £1.6 Million One-Time Gene Therapy Casgevy for Beta-Thalassaemia | iPharmaCenter

ipharmaservices

Aug 14, 2024

NICE Endorses Almirall's Ebglyss for Treating Moderate to Severe Atopic Dermatitis | iPharmaCenter

ipharmaservices

Jul 20, 2024

NICE Recommends Relugolix for Advanced Prostate Cancer Treatment

ipharmaservices

Jul 20, 2024

Hemgenix Receives Managed Access Recommendation for Treating Severe Haemophilia B in Adults | iPharmaCenter

ipharmaservices

Jul 14, 2024

NICE said NO to Keytruda plus trastuzumab for HER2-positive gastric cancer | 2024 | iPharmaCenter

NICE said NO to Keytruda plus trastuzumab for HER2-positive gastric cancer | 2024 | iPharmaCenter

NICE said NO to Keytruda plus trastuzumab for HER2-positive gastric cancer | 2024 | iPharmaCenter

ipharmaservices

Jun 13, 2024

Servier Laboratories' Tibsovo Combined with Azacitidine Recommended by NICE for Adult Patients with Newly Diagnosed AML with IDH1 Mutation | iPharmaCenter

ipharmaservices

Jun 7, 2024

NICE recommended AbbVie's Aquipta for migraine | United Kingdom |Healthcare News | iPharmaCenter

NICE recommended AbbVie's Aquipta for migraine | United Kingdom |Healthcare News | iPharmaCenter

NICE recommended AbbVie's Aquipta for migraine | United Kingdom |Healthcare News | iPharmaCenter

ipharmaservices

May 15, 2024

bottom of page